Vildagliptin + Metformin Dosage
For vildagliptin combined with metformin, use vildagliptin 50 mg twice daily (or 50 mg once daily if eGFR <50 mL/min/1.73 m²) plus metformin dosed according to renal function: start with 500-850 mg once daily and titrate weekly to maximum dose if eGFR ≥60, halve the dose if eGFR 30-44, and discontinue metformin entirely if eGFR <30.
Metformin Dosing Algorithm by Renal Function
The KDIGO 2022 guidelines provide clear metformin dosing based on eGFR 1:
eGFR ≥60 mL/min/1.73 m²
- Immediate release: Start 500 mg or 850 mg once daily
- Titrate upward by 500 mg/day or 850 mg/day every 7 days until maximum dose (2550 mg/day in divided doses)
- Extended release: Start 500 mg daily, titrate by 500 mg/day every 7 days
- Continue same dose without adjustment
eGFR 45-59 mL/min/1.73 m²
- Use same initiation and titration as above
- Consider dose reduction in certain high-risk conditions (acute illness, dehydration, contrast procedures)
- Monitor eGFR every 3-6 months instead of annually 1
eGFR 30-44 mL/min/1.73 m²
- Halve the dose from what would be used at higher eGFR
- If already on metformin, reduce current dose by 50%
- Maximum daily dose should be 1000 mg/day 2
- Monitor eGFR every 3-6 months 1
eGFR <30 mL/min/1.73 m²
- Stop metformin immediately; do not initiate 1, 2
- This is an absolute contraindication due to lactic acidosis risk
Vildagliptin Dosing by Renal Function
Vildagliptin requires dose adjustment based on renal function 3, 4:
eGFR ≥50 mL/min/1.73 m²
- 50 mg twice daily (total 100 mg/day)
- No dose adjustment needed
eGFR <50 mL/min/1.73 m² (moderate to severe renal impairment)
- 50 mg once daily (half the standard dose) 3, 4, 5
- This applies to both moderate (eGFR 30-50) and severe (eGFR <30) renal impairment
- Pharmacokinetic studies show vildagliptin AUC increases by 71% in moderate and 100% in severe renal impairment, justifying the dose reduction 4
Combination Therapy Considerations
Do not combine vildagliptin with GLP-1 receptor agonists - this is explicitly contraindicated as both work through incretin pathways 1. The KDIGO 2022 guidelines state DPP-4 inhibitors like vildagliptin should not be used with GLP-1 RAs 1.
When combining vildagliptin with metformin, studies demonstrate superior glycemic control compared to metformin monotherapy, with HbA1c reductions of approximately 0.59% greater when metformin doses ≥1500 mg/day are used 6. The combination shows a favorable safety profile with lower risk of gastrointestinal side effects compared to metformin alone 6.
Critical Monitoring Requirements
- Monitor eGFR: At least annually if eGFR ≥60, every 3-6 months if eGFR <60 1
- Monitor vitamin B12: Check levels after 4 years of metformin therapy 1
- Hypoglycemia risk: Low with this combination when used without sulfonylureas or insulin 1
- Discontinue metformin temporarily for iodinated contrast procedures if eGFR 30-60, and restart only after confirming stable renal function 48 hours post-procedure 2
Common Pitfalls to Avoid
- Don't continue metformin at full dose when eGFR drops below 45 - this significantly increases lactic acidosis risk
- Don't forget to reduce vildagliptin to once daily dosing when eGFR falls below 50 - the drug accumulates substantially with renal impairment 4
- Don't initiate metformin in patients with eGFR 30-45 - while continuation may be acceptable with dose reduction, initiation is not recommended 2
- Don't overlook acute illness or dehydration - these warrant temporary metformin discontinuation even if eGFR is adequate